TARGET GENE
GALC
TARGET ENZYME
Galactosylceramidase
PRIMARY
STORAGE
Galactosylsphingosine
SECONDARY
STORAGE
Alpha-synuclein
EPIDEMIOLOGY
1 : 100-250,000
UNMET MEDICAL NEED
No available treatment or cure
DEVELOPMENT
STAGE
Discovery
In vitro
GALC
Galactosylceramidase
Galactosylsphingosine
Alpha-synuclein
1 : 100-250,000
No available treatment or cure
Discovery
In vitro
Gain Therapeutics SA has been selected to present on March 26th, 2019.
Gain Therapeutics SA
announces that it has received funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA to advance its proprietary non-competitive pharmacological chaperones for Parkinson’s disease.
Wednesday, February 28
​
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain Therapeutics